Clinical Trial Update: A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating AK112 plus AK117 versus pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma; the study is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• AK112
• AK117 (AK117)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Akeso | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: RECRUITING